Cabozantinib shows activity in platinum-refractory bladder cancer

  • Apolo AB & et al.
  • Lancet Oncol
  • 6 Jul 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Cabozantinib monotherapy is well-tolerated and shows activity in patients with platinum-refractory metastatic urothelial carcinoma with measurable disease.

Why this matters

  • This is the first study to investigate a therapy targeting both angiogenic pathways and the MET receptor in this setting.
  • Findings provide a rationale for combining cabozantinib with immunotherapeutic strategies in future research.

Study design

  • Phase 2 trial.
  • 68 patients with metastatic platinum-refractory urothelial carcinoma received cabozantinib.
  • Funding: National Cancer Institute Intramural Program; Cancer Therapy Evaluation Program.

Key results

  • The median follow-up was 61.2 months.
  • In 42 evaluable patients with metastatic urothelial carcinoma with measurable disease:
    • 1 complete and 7 partial responses were reported.
    • Overall response rate was 19%.
    • Median PFS was 3.7 (95% CI, 3-6) months.
  • The most common grade 3-4 adverse events were fatigue, hypertension, proteinuria, and hypophosphatemia.
  • No treatment-related deaths were reported.

Limitations

  • Open label, no control group.